Nabi Biopharmaceuticals Announces Nabi Stockholder Meeting Results and the Approval of the Business Combination Transaction by

Nabi Biopharmaceuticals Announces Nabi Stockholder Meeting Results and the
Approval of the Business Combination Transaction by Biota Stockholders

ROCKVILLE, Md., Oct. 23, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals
(Nasdaq:NABI) announced today the results of the reconvened special meeting of
Nabi stockholders held on October 22, 2012 (the "Nabi Special Meeting"). Nabi
also announced that the stockholders of Biota Holdings Limited (ASX:BTA.AX)
approved the proposed business combination transaction between Nabi and Biota
at the meeting of Biota stockholders held on October 23, 2012 in Melbourne,
Australia.

Nabi stockholders voted at the Nabi Special Meeting to approve the following
proposals:

  oA proposal to approve an amendment to the Nabi Restated Certificate of
    Incorporation (the "Nabi Certificate of Incorporation") to increase the
    authorized shares of Nabi common stock from 125,000,000 shares to
    200,000,000 shares;
    
  oA proposal to approve an amendment to the Nabi Certificate of
    Incorporation to change the name of Nabi from "Nabi Biopharmaceuticals" to
    "Biota Pharmaceuticals, Inc.";
    
  oA proposal to approve an amendment to the Nabi Certificate of
    Incorporation to effect a reverse stock split of Nabi common stock at any
    time prior to December31, 2012 at a ratio ranging from four-to-one to
    eight-to-one, as determined by Nabi's board of directors in its sole
    discretion; and
    
  oA proposal to approve the issuance of shares of Nabi common stock to
    stockholders of Biota contemplated by the merger implementation agreement
    between Nabi and Biota, dated as of April 22, 2012, as amended.

Nabi stockholders voted at the Nabi Special Meeting not to approve the
proposal to approve, on an advisory (non-binding) basis, the compensation
payable to certain executive officers of Nabi under existing arrangements in
connection with the business combined transaction between Nabi and Biota.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals, headquartered in Rockville, Maryland, is a
biopharmaceutical company that has focused on the development of vaccines
addressing unmet medical needs, including nicotine addiction. Its sole product
currently in development is NicVAX^® (Nicotine Conjugate Vaccine), an
innovative and proprietary investigational vaccine for the treatment of
nicotine addiction and prevention of smoking relapse based on patented
technology. For additional information about Nabi Biopharmaceuticals, please
visit www.nabi.com.

CONTACT: Nabi Investor Relations
         301-770-3099
         www.nabi.com
        
         Morrow & Co., LLC
         Attn: Joe Mills
         203-658-9400
 
Press spacebar to pause and continue. Press esc to stop.